New Haven, Connecticut 06519


Purpose:

This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial of curcumin for the treatment of cognitive impairment in schizophrenia.The primary aim of this pilot trial is to provide an effect size estimate for the efficacy of curcumin in improving cognitive functioning in schizophrenia. Secondary goals are to determine the effect of curcumin over time on negative and positive symptoms, in association with inflammatory markers.


Study summary:

This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial of curcumin for the treatment of cognitive impairment in schizophrenia. Cognitive impairment and persistent negative symptoms are the core dimensions of schizophrenia; however current antipsychotic treatment fails to address this issue. Evidence suggests cognitive impairment is not only limited to patients with late-stage schizophrenia. High rates of cognitive impairment in patients with first episode psychosis indicate that cognitive impairment is not solely a consequence of long-term antipsychotic treatment, but rather is an enduring problem over the course of schizophrenia. Likewise, negative symptoms persist throughout its entire course, and are associated with poor overall functioning. Currently, there are no pharmacological agents that specifically aim to treat cognitive functioning and persistent negative symptoms; therefore, there is growing interest in the development of effective treatments for this unmet need. The primary aim of this pilot trial is to provide an effect size estimate for the efficacy of curcumin in improving cognitive functioning in schizophrenia. Secondary goals are to determine the effect of curcumin over time on negative and positive symptoms, in association with inflammatory markers. Eligible participants will be randomized to curcumin (n=20) or placebo (n=20) in a 1:1 ratio. A commercially available surface-controlled water soluble form of 600mg curcumin (10% formulation) or matching placebo capsules will be administered three times a day for a total of 8 weeks.


Criteria:

Inclusion criteria: 1. 18 - 65 years of age 2. English speaking 3. Diagnostic and Statistical Manual- IV diagnosis of schizophrenia or schizoaffective disorder based on Structured Clinical Interview for Diagnostic and Statistical Manual-IV (SCID) 4. Symptomatic stability confirmed by clinical staff in the 8 weeks prior to the study 5. No changes in antipsychotic medication within the last 8 weeks 6. No change in antipsychotic dose in in last 4 weeks. Exclusion criteria are: 1. Unable to provide informed consent 2. Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of alcohol/substance dependence 3. Recent history of gastrointestinal bleeding or ulceration 4. Recent history of gallstones and/or bile duct obstruction 5. Significant uncontrolled systemic illness (e.g. chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, chronic infectious disease, chronic autoimmune disease) 6. Known intolerance to turmeric, curcumin, or curry 7. Pregnancy or breast-feeding 8. Current use of anti-platelet, anti-coagulant, glucocorticoid, immunosuppressants 9. Daily use of non-steroidal anti-inflammatory use.


NCT ID:

NCT02476708


Primary Contact:

Principal Investigator
Cenk Tek, MD
Yale Unversity School of Medicine

Cenk Tek
Phone: 203-974-7484
Email: cenk.tek@yale.edu


Backup Contact:

N/A


Location Contact:

New Haven, Connecticut 06519
United States

Erin Sullivan
Phone: 203-974-7317
Email: erin.sullivan@yale.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.